SCLXbenzinga

Scilex Announces Approval Of New Drug Submission From Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy And Neurological Sciences For ELYXYB's Acute Treatment of Migraine With or Without Aura In Canada

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 15, 2025 by benzinga

    Scilex Announces Approval Of New Drug Submission From Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy And Neurological Sciences For ELYXYB's Acute Treatment of Migraine With or Without Aura In Canada | SCLX Stock News | Candlesense